A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
A phase 3 trial of Inavolisib, Fulvestrant and Alpelisib in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, now recruiting.
Overview
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy is a phase 3 interventional study registered as NCT05646862 by Hoffmann-La Roche, with 420 participants planned, started 2023-06-07 and due to reach its primary completion in 2026-11-13. Interventions recorded: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole and Midazolam.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Shares Inavolisib, Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Shares Inavolisib, Flatiron Health (Roche), Fulvestrant and the tag pipeline.
- TrialA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Shares Inavolisib, Flatiron Health (Roche), Fulvestrant and the tag pipeline.
- TrialStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Shares Alpelisib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Shares Flatiron Health (Roche), Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Shares Inavolisib, Flatiron Health (Roche) and the tag pipeline.
- TrialStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Shares Alpelisib, Fulvestrant and the tag pipeline.
- TrialStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Shares Alpelisib, Fulvestrant and the tag pipeline.